Vedolizumab for extraintestinal manifestations in pediatric inflammatory bowel disease: Results from the VedoKids study
J Pediatr Gastroenterol Nutr. 2025 Nov 18. doi: 10.1002/jpn3.70276. Online ahead of print. ABSTRACT Extraintestinal manifestations (EIMs) manifest in 6%-47% of patients with inflammatory bowel …